Introduction
The protein kinase C (PKC) family encompasses a group of serine/threonine kinases that have important roles in many cellular processes. This family consists of ten isoforms that are divided into three subclasses: conventional (PKCα, PKCβI, PKCβII and PKCγ), novel (PKCδ, PKCε, PKCη and PKCθ) and atypical (PKCζ and PKCι) . This classification is based on their sensitivity for the second messengers calcium and diacylglycerol. The conventional isoforms respond to both activators, whereas novel PKCs only react to diacylglycerol, and atypical PKCs are not activated by either calcium or diacylglycerol.
Recently, PKCγ (also known as PRKCG) was identified as the disease-causing gene for the neurodegenerative disorder spinocerebellar ataxia type 14 (SCA14) . SCA14 is characterized by a slowly progressive cerebellar ataxia accompanied by slurred speech and abnormal eye movements. The ataxic syndrome is due to loss of Purkinje cells leading to cerebellar neurodegeneration. PKCγ is the brain-specific member of the PKC family and is highly expressed in Purkinje cell soma and dendritic processes, and regulates expression of long-term depression at the parallel fiber of the Purkinje cell synapse, controlling synaptic plasticity (Daniel et al., 1998; Schrenk et al., 2002) . Furthermore, PKCγ activity seems to control the elimination of climbing fibers during cerebellar development because Purkinje cells from PKCγ mutant mice persist with multiple climbing fibers into adulthood Kano et al., 1995) . These studies show the importance of PKCγ activity in Purkinje cell development and neuronal connectivity; however, the molecular mechanisms by which PKCγ controls these processes are still poorly understood.
Whereas many types of SCA are caused by coding polyglutamine repeat expansion mutations in the encoding proteins, missense mutations in PKCγ were identified to cause SCA14 in families with different genetic backgrounds (Alonso et al., 2005; Chen et al., 2003; Dalski et al., 2006; Fahey et al., 2005; Klebe et al., 2005; Stevanin et al., 2004; van de Warrenburg et al., 2003; Vlak et al., 2006; Yabe et al., 2003) . Up to now, 23 different mutations have been identified throughout the coding region of PKCγ, although about 75% of all SCA14 mutations are located in the highly conserved C1B subdomain of the regulatory domain of PKCγ. The impact of SCA14 missense mutations in this particular subdomain remains unknown, but we hypothesized that the mutated amino acids are possibly crucial for the structure of the C1B subdomain and could therefore induce conformational changes leading to altered regulation of PKCγ activity.
PKC remains inactive in a 'closed' conformation via intramolecular interactions. This involves binding of the pseudoinhibitory substrate that is localized at the N-terminus of the variable protein region (V1 domain) to the substrate-binding core in the catalytic domain (Pears and Parker, 1991) . In addition, three phosphorylation events are required for PKC to become fully maturate, but still inactive. The first phosphorylation step is catalyzed by phosphoinositide-dependent protein kinase 1 (PDPK1), which is followed by two autophosphorylation events (Dutil et al., 1994; Dutil et al., 1998) . Upon activation, PKC rapidly translocates from the cytoplasm to the plasma membrane and interacts with phospholipids, leading to the release of the pseudo-inhibitory substrate from the catalytic domain resulting in an 'open' and active conformation (Newton, 2001) . This translocation process is initiated by calcium binding to the C2 domain and the subsequently binding of diacylglycerol to the two C1 subdomains C1A and C1B (Newton, 2004; Oancea and Meyer, 1998; Rodriguez-Alfaro et al., 2004; Sakai et al., 1997) . In the case of PKCγ, C1A and C1B bind its ligand with comparable affinity in vitro . The V1-domain that contains the pseudo-inhibitory substrate controls the accessibility of the C1 domain for phorbol ester, which guarantees that PKC is sequentially activated by calcium and diacylglycerol signals (Oancea and Meyer, 1998) . In addition, masking of the phorbol ester binding sites in the C1 domain is also regulated via intramolecular interactions between the C2 domain and the C-terminal V5 domain, because mutations in these domains make PKCα respond to DAG and increase the phorbol sensitivity of PKCβ (Stensman and Larsson, 2007) .
Here we show that SCA14 mutations located in the C1B subdomain enhance PKCγ translocation from cytoplasm to plasma membrane upon phorbol ester stimulation when compared with wild-type PKCγ. These mutations apparently increase the accessibility of the C1 domain for phorbol ester by unmasking the phorbol ester binding sites of the C1 domain. Fluorescence lifetime imaging microscopy (FLIM) analysis using YFP-PKCγ-CFP fusion proteins showed significantly lower intramolecular FRET signals when SCA14 mutations are present, demonstrating that the C1B subdomain mutations result in an 'open' protein conformation. Surprisingly, the increased kinetics resulted in a decrease of PKCγ kinase function upon activation. By using the PKC phosphorylation reporter MyrPalm-CKAR, we show that the mutations causing SCA14 reduce PKCγ kinase activity in living cells. In addition, reduced extracellular signal-regulated kinase (ERK) nuclear translocation, and ERK phosphorylation was also observed in cells expressing mutant PKCγ. Together, these findings show that reduced PKCγ activity and aberrant mitogen-activated protein kinase (MAPK) signaling underlies SCA14.
Results

PKCγ protein expression and subcellular localization
In order to investigate the effects of SCA14 mutations on the intracellular distribution and kinetics of PKCγ in living cells, we generated both green and red fluorescently tagged (GFP/RFP) fusion proteins of both wild-type and SCA14 mutant PKCγ. In addition, we generated similarly tagged fusion proteins for the isolated C1B subdomains (Fig. 1B) . The SCA14 mutations that were used in this study include G118D, V138E and C142S (van de Warrenburg et al., 2003; Vlak et al., 2006) (Fig. 1A) , which are all located in the C1B subdomain. Both full-length PKCγ and C1B were transiently expressed in HEK293T cells, followed by the analysis of cell lysates by western blotting, which showed that all constructs were efficiently expressed (Fig. 1C) . Visualization of the intracellular distribution of the proteins in living cells showed that PKCγ had a cytoplasmic distribution, whereas the much smaller C1B subdomain was distributed throughout the cytoplasm and nucleus (Fig. 1D ). The three SCA14 mutations did not alter the cellular distribution of either fulllength PKCγ or the C1B subdomain.
No massive aggregation was observed in cells expressing wild-type or mutant PKCγ, as was shown by Seki and colleagues (Seki et al., 2005) . Only a low percentage of cells showed accumulation of full-length PKCγ-GFP protein in the perinuclear region of the cells, probably because of high levels of PKCγ overexpression (data not shown). (Kazanietz et al., 1995; Xu et al., 1997) . Val138Gly and Cys142Gly mutations completely abolish phorbol ester binding to the C1B subdomain. Given the homology between the different isoforms, we aimed at investigating whether the SCA14 mutations G118D, V138E and C142S would affect PKCγ activation upon phorbol ester stimulation.
We started by measuring the kinetics of PMA-induced translocation of both wild-type C1B and mutant C1B subdomains in living cells. Initially, all experiments were performed using single plasmid transfections; however, to exclude cell-cell variation and to get a more accurate comparison between wild-type and mutant, co-transfection experiments were carried out with wild-type GFP and PKCδ mutant RFP plasmids. Similar results were obtained for both experiments (data not shown). HeLa cells were cotransfected with both wild-type C1B-GFP and mutant C1B-RFP to simultaneously image both translocation events using confocal microscopy. The translocation kinetics of G118D mutant C1B subdomain by PMA was similar to wild-type C1B ( Fig. 2A,B) . By contrast, no translocation of the V138E and C142S mutant C1B subdomains was observed upon PMA stimulation. Similar results were obtained when the GFP and RFP fluorophores were exchanged between the wild-type and mutant domains, excluding the possibility that this effect is fluorophore dependent (data not shown). Taken together, the results demonstrate that SCA14 mutations, which are all located in the C1B subdomain, apparently work via a different mechanisms, because some, but not all, of the disease-related mutations abolish PMA-induced translocation.
Next, we examined whether the SCA14 mutations also affect PMA kinetics of full-length PKCγ, because it has been shown that the C1A subdomain of PKCγ can also bind PMA with comparable affinity as C1B (Ananthanarayanan et al., 2003) . Therefore, we repeated the PMA-induced translocation experiment using fulllength wild-type PKCγ-GFP and mutant PKCγ-RFP. Surprisingly, none of the SCA14 mutations impaired PMA-induced translocation, but resulted in enhanced translocation kinetics when compared with wild-type PKCγ (Fig. 3A,B) . This effect was also not dependent on the fused fluorophores, because exchange of the GFP and RFP fluorophores showed identical results (data not shown). Increased PMA-induced translocation has also been observed for a PKCγ with a deleted V1 domain, which contains the pseudo-inhibitory substrate (Oancea and Meyer, 1998) . Their results suggest that the accessibility of the C1 domain for phorbol ester is restricted by a 'clamp' between the V1 domain and the catalytic domain. Removal of the V1 domain results in an 'open' protein conformation, which leads to exposure of the phorbol binding sites in the C1 domain. To test whether SCA14 mutations in PKCγ lead to similar translocation kinetics, we compared the kinetics of SCA14-mutant PKCγ-GFP and deleted V1 mutant, deltaV1-PKCγ-GFP upon PMA stimulation. Both mutants showed similar rates of translocation upon PMA stimulation, suggesting that SCA14 mutations may affect the regulation of the catalytic domain by the V1-clamp (Fig. 3C ). In addition, we also tested whether the constitutively active pseudosubstrate mutant A24E-PKCγ showed increased translocation kinetics upon PMA stimulation. The A24E mutation leads to constant exposure of the pseudosubstrate, leading to complete abolishment of the V1-clamp to the catalytic domain and induces therefore an 'open' protein conformation (Pears et al., 1990) . Indeed, the translocation kinetics of A24E-PKCγ to the plasma membrane upon PMA stimulation was similar to deltaV1-PKCγ and SCA14-mutant PKCγ (data not shown).
These data suggest that the enhanced translocation kinetics of SCA14 mutant PKCγ upon PMA stimulation might result from increased accessibility of the overall C1 domain for phorbol ester, as a result of conformation changes under the influence of diseaserelated mutations in the PKCγ protein.
SCA14 mutant PKCγ shows increased membrane targeting without affected C2 domain functioning
As PKC is sequentially activated by calcium (C2 domain) and phorbol ester (C1 domain), we wanted to determine the effect of a physiological stimulus on the translocation kinetics of PKCγ. Therefore, we tested whether SCA14 mutations would affect histamine stimulation of PKCγ, because activation of the histamine receptor induces the rapid release of endoplasmic-reticulum-stored calcium and production of diacylglycerol. HeLa cells were transiently cotransfected with wild-type (red) and SCA14-mutant (green) PKCγ and imaged in real time using histamine stimulation and subsequent PMA and ionomycin treatment to obtain full PKCγ translocation. Although no difference was detected in the translocation pattern between two wild-type PKCγ protein fused to GFP and RFP (Fig. 4A) , the amplitude of translocation of the SCA14 mutant PKCγ was 1.5±0.03 (G118D; mean ± s.e.m.), 1.9±0.1 (V138E) and 1.4±0.05 (C142S) times significantly increased when compared with wild-type PKCγ (G118D; V138E; C142S unpaired t-test, n=3-5; P=0.0002, P=0.0026 and P=0.0007, respectively) ( Fig.  4B -E). The graphs are representatives of at least three independent experiments. These results indicate that the SCA14 mutations enhance the amount of PKCγ protein at the plasma membrane upon stimulation of cells under physiological conditions.
To resolve whether the enhanced membrane targeting of SCA14-mutant PKCγ was solely caused by the increased accessibility of the C1 domain for phorbol ester or also by changes in Ca 2+ binding to the C2 domain, we measured PKCγ translocation to the plasma membrane upon Ca 2+ ionophore stimulation. This ionophore activation will result in opening of Ca 2+ pores in the plasma membrane leading to a rapid increase in intracellular Ca
2+
. No difference in translocation kinetics was observed between wild-type and SCA14 mutant PKCγ (Fig. 4F ), indicating that stimulation via the C2 domain was not affected.
Overall, these results show that SCA14 mutations located in the C1B subdomain principally affect the phorbol ester sensitivity of the C1 domain, which leads to increased membrane targeting of SCA14 mutant PKCγ.
Unmasking of the C1 domain via SCA14 mutations is associated with altered PKCγ conformation
Our kinetic studies suggest that the SCA14 mutations located in the C1B subdomain unmask the C1 domain, leading to exposure and increased accessibility of the phorbol ester binding sites. This could be the result of destabilization of the 'closed' conformation, Journal of Cell Science 121 (14) which will consequently provoke unmasking of the C1 domain. To examine the differences in PKCγ protein conformation caused by C1B SCA14 mutations, we took advantage of fluorescence resonance energy transfer (FRET) analysis. It has been shown previously that intramolecular FRET can be used to probe protein conformation in single living cells by tagging the protein of interest with both a donor and an acceptor fluorophore (Giepmans et al., 2006; Miyawaki, 2003) . The FRET signal is dependent on the distance and orientation of the two fluorophores and altered protein conformations of PKCγ may lead to a changed distance between the N-and C-terminus and subsequent change in the FRET signal. PKCγ FRET constructs were generated by tagging the N-terminus with EYFP and the Cterminus with ECFP.
To examine whether FRET can be used to distinguish between different conformations, we measured FRET efficiencies of the wild-type PKCγ, which is in a 'closed' conformation, and the A24E mutant which cannot bind the pseudosubstrate (N-terminus) to the substrate-binding grove and consequently remains in an 'open' conformation. Although FRET was observed in these constructs, no differences in FRET efficiency were measured (data not shown). Since it is known that the ECFP and EYFP have the tendency to dimerize, the ECFP was replaced by a monomerized, brighter variant (Kremers et al., 2006) , to abolish intramolecular dimerization. FLIM was used to measure FRET efficiencies (van Munster and Gadella, 2005) using SCFP3A as a control. Both phase and modulation lifetimes of SCFP3A were strongly reduced in the wild-type YFP-PKCγ-SCFP3A protein, yielding a FRET efficiency of 29% ( Fig. 5A-C) . By contrast, the SCFP3A lifetime of the A24E-PKCγ mutant was close to values of the unquenched SCFP3A with a relatively low FRET efficiency of 11% based on the phase lifetime (Fig. 5B,C) and 10% based on the modulation lifetime. These results fit with the model in which the N-and C-terminus are close together in the closed conformation of inactive wild-type PKCγ, whereas the termini are further apart into an open conformation of the constitutively active A24E mutant. These results showed that intramolecular FRET can be used to distinguish between the closed and open PKCγ conformation in unstimulated cells. When we monitored the changes in protein conformation upon activation of PKC by PMA, we consistently observed a FRET increase for all constructs (data not shown), whereas a decrease was expected, as this would correspond to the open active conformation. Similar observations have been reported for the PKCδ isoform (Braun et al., 2005) . This can be explained by accumulation of PKC at the plasma membrane induced by PMA. Owing to the relative high surface concentration of PKC molecules at the plasma membrane, intermolecular aspecific FRET takes place. Therefore, this approach did not allow monitoring changes in conformation upon activation of PKC.
Subsequently, we incorporated the SCA14 mutations, G118D, V138E and C142S into the wild-type PKCγ FRET construct. The SCA14 mutant PKCγ gave rise to significantly lower FRET signals than wild-type PKCγ (G118D; V138E; C142S, all P<0.0001, unpaired t-test, n=5) ( Fig. 5A-C) . The three SCA14 mutant PKCγ displayed approximately similar FRET efficiencies ranging from 14% to 16% (Fig. 5C) , based on the phase lifetime (and 11-12% based on the modulation lifetime). Interestingly, these FRET signals were similar to the value measured for A24E-PKCγ (Fig. 5A,B) . Although the FRET efficiency measured in the SCA14 mutants and A24E mutant is significantly reduced relative to wild-type PKCγ, it cannot be concluded from these experiments that the conformations are identical. All proteins were properly expressed, excluding the possibility that the lower FRET signal was due to degradation of the SCA14-mutant PKCγ proteins (data not shown).
In conclusion, these results demonstrate that SCA14 mutations located in the C1B subdomain change PKCγ from a closed conformation into a different, most likely, open conformation in which the C-and N-termini are further apart.
SCA14 mutant PKCγ shows reduced kinase activation in living cells
Since SCA14 mutant PKCγ display enhanced PMA kinetics and exhibit a different protein conformation, we hypothesized that C1B SCA14 mutations alter the phosphorylation capacity and thus activity of PKCγ. In order to measure PKCγ activity in living cells, we used the PKC phosphorylation reporter, MyrPalm-CKAR, which is a membrane-bound intramolecular FRET reporter (Violin et al., 2003) . Immediate phosphorylation of the PKC substrate sequence upon PKC activation causes a conformational change that reduces the amount of FRET between the CFP and YFP fluorophores. Unfortunately, the PKC-substrate peptide sequence is not selectively accessible for PKCγ but also permits phosphorylation of PKCα and PKCβ. Therefore, we first tested whether activation of expressed wild-type PKCγ would lead to lower FRET ratios than activation of endogenous PKC (α and β) levels in HeLa cells. HeLa cells were transiently transfected with MyrPalm-CKAR or cotransfected with wild-type PKCγ-RFP. First, we stimulated the cells with histamine, which only induced partial phosphorylation of MyrPalm-CKAR, but did not show much difference in FRET ratio and magnitude of activation between cells overexpressing wild-type and endogenous PKC in response to histamine (Fig. 6A) . Since cells react rather heterogeneously to stimulation by histamine, we decided to subsequently add PMA to obtain the maximal amplitude of the reporter corresponding to maximal phosphorylation. Cells overexpressing PKCγ showed significant lower FRET ratios (24.2±0.4; mean ± s.e.m.) (P<0.0001, unpaired t-test, n=5) compared with cells that did not express PKCγ (15.3±0.2), demonstrating that we could detect PKCγ-specific CKAR phosphorylation (Fig. 6A) . We then investigated whether changes in PKCγ protein conformation due to unmasking of the C1 domain are reflected in a different MyrPalm-CKAR FRET ratio. Surprisingly, significantly lower FRET efficiencies (G118D; V138E; C142S: 20.6±0.4; 18.4±0.5; 18.0±0.6; mean ± s.e.m.; P=0.0002; P=0.0001; P<0.0001, unpaired t-test, n=3-5) were observed in cells expressing SCA14 mutant PKCγ than cells containing wild-type PKCγ upon PMA stimulation, indicating less MyrPalm-CKAR phosphorylation (Fig. 6B) . These results suggest that the SCA14 mutant PKCγ has less capability to phosphorylate cellular substrates and thus subsequently exhibit reduced kinase activity in living cells. This finding was confirmed in cell lysate of cells overexpressing wild-type or SCA14 mutant PKCγ using an anti-phosphoserine-PKC-substrate antibody. We observed an overall reduction in kinase activity in cell lysates of SCA14 mutant PKCγ when compared with wild-type PKCγ, because a number of unidentified PKC targets showed a reduction in phosphorylation upon PMA stimulation (data not shown). To examine whether reduced SCA14 mutant PKC activity upon activation is the result of increased basal membrane activity due to the open conformation, we used the PKC inhibitor Gö6976 to block basal PKC activity. Upon addition of Gö6976 to unstimulated cells expressing either wild-type PKCγ or SCA14 mutant PKCγ, we observed similar increased YFP/CFP FRET ratios in both cases (data not shown). This result suggests that the MyrPalm-CKAR reporter is constitutively phosphorylated to a similar extent by either wild-type PKCγ or SCA14 mutant PKCγ.
Since these experiments only report on the phosphorylation of an artificial substrate or unknown PKC targets, we also wanted to examine whether relevant cellular target proteins were also affected by reduced phosphorylation. Therefore, we studied the phosphorylation status of the known intracellular PKC target myristoylated alanine-rich C-kinase substrate (MARCKS). MARCKS is a multifunctional protein implicated in cell motility, membrane trafficking and mitogenesis, because its activity regulates growth cone adhesion and pathfinding (Gatlin et al., 2006; Myat et al., 1997 wild-type or SCA14 mutant PKCγ upon PMA activation, using an anti-phospho-MARCKS antibody. Immunoblotting showed no basal phosphorylation of MARCKS, but when PMA was added, reduced MARCKS phosphorylation in cells expressing SCA14 mutant PKCγ was observed compared with that in cells containing wild-type PKCγ (Fig. 6C,D) .
These experiments demonstrate that SCA14 mutations located in the C1B subdomain affect PKCγ kinase activity, resulting in reduced phosphorylation of downstream targets.
SCA14 mutant PKCγ affects downstream MAPK signaling
The MAPK pathways that activate ERK play an important role in cell mobility, cell migration, dendrite spine plasticity and long-term potentiation in learning and memory functions (De Zeeuw et al., 1998; Pullikuth and Catling, 2007; Robinson et al., 1998) . Misregulation of cell migration has already been associated with neurodegeneration (Hafezparast et al., 2003; Vallee et al., 2001) and as result, we hypothesized that aberrant MAPK and ERK signaling may be affected in SCA14. The movement of ERK2 into the nucleus has been suggested to be important for the long-term consequences of ERK activation (Horgan and Stork, 2003) . Therefore, we determined ERK2 cytoplasmic-nuclear shuttling using confocal microscopy. GFP-ERK2 was transiently transfected in HeLa cells either with wild-type PKCγ-RFP or SCA14 mutant PKCγ-RFP and stimulated them with PMA. PKC activation induced a transient GFP-ERK2 nuclear translocation within 10 minutes of addition of PMA (Fig. 7A,B) . Translocation analysis showed a significant reduction in nuclear accumulation (G118D; V138E; C142S: P=0.0024; P=0.0009; P=0.0011, unpaired t-test, n=3) of GFP-ERK2 in the nucleus of cells coexpressing SCA14 mutant PKCγ (G118D; V138E; C142S: 2.0±0.04; 1.7±0.03; 1.7±0.06; mean ± s.e.m.) compared with cells coexpressing wild-type PKCγ (3.0±0.1) or cells only expressing GFP-ERK2 (2.9±0.1) (Fig.  7B,C) . To exclude the idea that reduced nuclear ERK translocation was caused by basally higher ERK levels in the nucleus of cells coexpressing SCA14 mutant PKCγ, we determined nuclear ERK2-GFP expression levels of cells coexpressing either wild-type PKCγ or SCA14 mutant PKCγ using western blotting. No increased nuclear ERK2-GFP expression was observed in cells expressing SCA14 mutant PKCγ compared with that cells expressing wild- type PKCγ (data not shown). As nuclear accumulation is associated with ERK phosphorylation (Costa et al., 2006) , we also determined the phosphorylation profile of endogenous ERK in cells upon PKC activation. Notably, no significant basal phosphorylation of ERK was observed in unstimulated cells overexpressing wild-type PKCγ or any of the SCA14 mutants. In accordance with the translocation assay, reduced levels of ERK phosphorylation were observed in cells expressing SCA14 mutant PKCγ when compared with cells expressing wild-type PKCγ (Fig. 7D,E) .
Together these data show that SCA14 mutations located in the C1B subdomain affect PKCγ kinase activity, lead to lower ERK phosphorylation levels and accordingly reduce nuclear ERK translocation. Both events will reduce MAPK signaling, and might therefore lead to reduced expression of target genes affecting neurite outgrowth and survival.
Discussion
In resting cells, the accessibility of the C1 domain for phorbol ester is well regulated by masking of the C1 domain, which prevents exposure of the phorbol binding sites. This 'closed' protein conformation is necessary to keep PKC inactive. Although two SCA14 mutations, V138E and C142S, completely abolish translocation of the isolated C1B subdomain to the plasma membrane upon phorbol ester stimulation ( Fig. 2A,B) , the G118D mutation does not seem to affect C1B PMA-induced kinetics. However, when present in the full-length PKCγ protein, all three SCA14 mutations enhanced PKCγ translocation to the plasma membrane upon phorbol ester stimulation (Fig. 3A,B) . These finding suggest that SCA14 mutations not only affect the regulatory function of C1B subdomain, but also affect the C1A domain. This possibility would reconcile our findings with previous studies showing that the C1A and C1B subdomains of PKCγ have similar affinities for phorbol ester in vitro (Ananthanarayanan et al., 2003) . They thus have redundant roles in PKCγ phorbol ester activation, because even the SCA14 mutant PKCγ lacking a functional C1B subdomain showed enhanced PMA-induced translocation. Furthermore, the residues V138 and C142 have already been shown to be crucial for phorbol ester binding (Kazanietz et al., 1995) , and modelling of the crystal structure of the C1B subdomain also demonstrated that the mutated residues indeed led to a dysfunctional phorbol ester binding site (our unpublished data). Interestingly, despite proper C1B subdomain activation upon phorbol ester stimulation, the G118D mutation also enhanced the translocation kinetics of the full-length PKCγ protein, similarly to the other mutated proteins. Apparently, the Journal of Cell Science 121 (14) SCA14 mutations affect PKCγ activation via a different mechanism but with a similar outcome. Enhanced PKCγ translocation upon phorbol ester stimulation was also observed when the V1-domain containing the pseudoinhibitory substrate was deleted in PKCγ. This study showed that removal of the V1-domain increased the accessibility of the C1 domain for phorbol ester (Oancea and Meyer, 1998) . SCA14 mutations located in the C1B subdomain apparently affect PKCγ kinetics in a similar way, by altering the conformation of the protein, leading to unmasking of the C1 domain as was shown in Fig. 3C . The changed conformation of the SCA14 mutants also became obvious from our FRET studies (Fig. 5) . We showed that all three SCA14 mutations led to an open PKCγ protein conformation, which may be similar to that of PKCγ with mutations in the V1 domain (ΔV and A24E), because all three variants showed enhanced PMA-induced kinetics.
Although the SCA14 mutations in the C1B subdomain showed similar kinetics and conformational changes as modification or deletion of the upstream V1-domain, they could also affect functioning of the other regulatory domain, the C2 domain (Oancea and Meyer, 1998; Slater et al., 2002; Stahelin et al., 2005; Stensman et al., 2004) . However, we did not observe any effect of the SCA14 mutations on C2 functioning as measured by PKCγ calcium sensitivity (Fig. 4E) . Furthermore, the SCA14 mutations located in the C1B subdomain did not impair PKCγ membrane dissociation as shown by the reversible histamine translocation. However, SCA14 mutant PKC did show increased membrane binding upon histamine stimulation, demonstrating that SCA14 mutant PKCγ has increased affinity for the plasma membrane under physiological conditions (Fig. 4A-D) .
As enhanced PMA kinetics and open PKC protein conformations are always associated with active PKC, we hypothesized that SCA14 mutant PKCγ would increase signaling pathways upon activation. To our surprise, the SCA14 mutations located in the C1B subdomain reduced PKCγ kinase activity in living cells as demonstrated using the fluorescent membrane-bound reporter MyrPalm-CKAR (Fig.  6) . Moreover, both MARCKS and a more downstream target ERK2 showed reduced PKCγ-mediated phosphorylation, which led to reduced MARCKS and MAPK activation in living cells (Fig. 6C and Fig. 7) . Importantly, we did not observe enhanced basal phosphorylation of CKAR, MARCKS or ERK as a result of overexpression of SCA14 mutants. These results suggest that if the SCA14 mutants have increased basal activity, this activity is effectively counteracted in cells by phosphate activity.
PKC has been shown to regulate the structure and function of the cell by phosphorylating various cytoskeletal or functional proteins, such as MARCKS or annexins (Keenan and Kelleher, 1998) . MARCKS has been implicated in regulating cell attachment, membrane ruffling and spreading (Myat et al., 1997) . Furthermore, its activity is important for the reorganization of cytoskeletal structures, which are crucial events in growth cone formation and dendrite outgrowth (Geddis and Rehder, 2003; Matsuoka et al., 1998) . Although there may be several possibilities that may explain the SCA14 disease pathology, defects in MARCKS-dependent cell adhesion or spreading may explain the neurodegenerative phenotype. The role of ERK signaling in neurodegenerative disorders is more complex, because both protective and deleterious roles for ERK activation in neuronal cells have been described (Apostol et al., 2006; Colucci-D'Amato et al., 2003; Lievens et al., 2005) . The diversity of ERK activation is not surprising, because the pathway integrates various signals depending on the cellular context, including cell proliferation, differentiation, migration and survival (Bhalla and Iyengar, 1999; Chuderland and Seger, 2005; Hetman and Gozdz, 2004) . This diversity is also mediated by several factors, such as cell or tissue type, the duration of activation, as well as the subcellular localization (Ebisuya et al., 2005) . However, our results suggest that reduced ERK signaling underlies SCA14 disease.
To address the question of how increased PKCγ kinetics resulting from an open conformation corresponds to reduced activity, we are currently studying the maturation process of SCA14 mutant PKCγ and performing membrane-binding studies to determine maximal PKC activity upon membrane interactions. We suggest that an open PKCγ protein conformation at resting state affects its maturation process via PDPK1. The maturation of PKCs after synthesis involves the phosphorylation of the enzyme at multiple serine/threonine sites. Phosphorylation by PDPK1 is the first phosphorylation event in this maturation process and acts as an onoff switch for PKC activity. As PDPK1 preferably interacts and covalently modifies substrates when they are in open conformations (Sonnenburg et al., 2001) , we hypothesize that SCA14 mutations affect the proper maturation process of PKCγ leading to reduced PKC kinase activity.
Interestingly, the neurological phenotype of SCA14 patients (heterozygous mutations) is more severe than that of the PKCγ-knockout mice . Therefore, the increase in SCA14 mutant PKCγ kinetics but decrease in activity may explain the dominant-negative effect of the mutated PKCγ protein, because it might compete with wild-type PKCγ for its ligands at the plasma membrane. A similar competition between PKC isoforms for phorbol ester binding has been observed previously (Lenz et al., 2002) , where agonist stimulation induced selective membrane recruitment of classical and/or novel PKC isoforms. This phenomenon may also explain why even less ERK phosphorylation was observed in cell lines overexpressing SCA14 mutant PKCγ compared with cells that did not overexpress PKCγ (Fig. 7D) .
Although SCA14 is caused by mutations in the PKCγ gene, other SCA types that show comparable disease phenotypes are caused by mutations in genes encoding other signaling proteins. These proteins include tau-tubulin-associated kinase 2 (SCA11), α1 subunit of the P/Q-type calcium channel (SCA6), regulatory subunit of the protein phosphatase PP2A (SCA12) and fibroblast growth factor 14 (SCA27) (Holmes et al., 2001; Houlden et al., 2007; van de Leemput et al., 2007; van Swieten et al., 2003; Zhuchenko et al., 1997) . Future research is required to determine whether these different proteins are components of shared signaling routes or even are linked within one common signaling cascade that underlies SCA disease in general. Furthermore, FGF signaling, Ca 2+ influx and phosphatase activity also regulate PKC functioning, and place PKCγ at an important position in neuronal signaling pathways. Therefore, it is not surprising that PKC is involved in various diseases, such as cancer, cardiac and lung diseases, diabetes and neurodegenerative disorders, such as SCA14. To select PKC as a target for therapeutic approaches, we need to know more about PKC isoform differences to generate selective inhibitors or activators. Nevertheless investigating 'naturally occurring' PKC mutations may help us to understand the mechanisms of PKC activation and regulation and the subsequent effects on downstream signaling.
In conclusion, we show that SCA14 mutations located in the C1B subdomain of PKCγ enhance PMA-induced kinetics and an open PKCγs protein conformation. This results in increased membrane targeting upon physiological stimuli but leads to decreased kinase activity and downstream MAPK signaling. We propose that SCA14 mutations unmask the C1 domain, expose the phorbol binding sites by opening of the PKCγ protein conformation, which subsequently results in increased accessibility of the whole C1 domain for phorbol ester. The increased accessibility subsequently leads to increased PMA translocation kinetics. Unexpectedly, these events corresponded with decreased kinase activity, as shown by the reduced phosphorylation capacity of PKCγ in living cells. As a consequence, SCA14 mutant PKCγ reduced ERK activation, which highlights the MAPK signaling pathway for possible therapeutic intervention in SCA14 disease.
Materials and Methods
DNA constructs
The wild-type and SCA14 mutant Gly118Asp PKCγ-GFP constructs were described previously (Verbeek et al., 2005) . The Val138Glu and the Cys142Ser mutations were introduced into PRKCG cDNA with the Quikchange II Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA). For the Val138Glu and the Cys142Ser mutations the following primers were used: Val138Glu forward, 5Ј-GTC GCG AGA TGA ACG AGC ACC GGC GCT GTG TG-3Ј; Val138Glu reverse, 5Ј-CAC ACA GCG CCG GTG CTC GTT CAT CTC GCA GC-3Ј; Cys142Ser forward, 5Ј-CGT GCA CCG GCG CTC TGT GCG TAG CGT GC-3Ј; and Cys142Ser reverse, 5Ј-GCA CGC TAC GCA CAG AGC GCC GGT GCA CG-3Ј. The CIB cDNAs were amplified from the corresponding PKCγ-GFP constructs by PCR using the following primers: forward, 5Ј-GCC GAA TTC ACC ATG CAC AAG TTC CGC CTG CAT AG-3Ј and reverse, 5Ј-CGG GGA TCC CGG CAC AGG GAG GGC ACG CT-3Ј generating an EcoRI site at the 5Ј end and a BamHI site at the 3Ј end. This facilitated cloning into the EGFP-N1 plasmid. In addition, the EGFP-N1 plasmid (Clontech) was replaced by a RFP-N1 expression vector (Campbell et al., 2002) . The MyrPalm-CKAR construct and YFP-PKCδ-CFP were kindly provided by A. Newton (University of California at San Diego, La Jolla, CA) and by B. Blumberg (National Cancer Institute NIH, Bethesda, MD), respectively. The EYFP-PKCδ-ECFP construct was used as template to generate the EYFP-PKCγ-ECFP and the EYFP-PKCγ-SCFP3A constructs. PKCδ was removed from the EYFP-ECFP vector using XhoI and BamHI. Wild-type and SCA14-mutant PKCγ inserts flanked with XhoI and BamHI site were amplified from the corresponding PKCγ-GFP plasmids using the following primer: forward, 5Ј-GCC CTC GAG ACC ATG GCT GGT CTG GGC CCC-3Ј and reverse, 5Ј-CGG GGA TCC CGC ATG ACG GGC ACA GGC AC-3Ј creating XhoI and BamHI sites on the 3Ј end and 5Ј end, respectively. The ECFP was subsequently replaced with SCFP3A, a previously described brighter, monomeric variant of CFP (Kremers et al., 2006) , using the flanking BamHI and NotI restriction sites. The GFP-MARCKS construct was kindly provided by H. Mogami (Hamamatsu University School of Medicine, Hamamatsu, Japan) and the GFP-ERK2 was cloned by P. Stork (Oregon Health & Science University, Portland, OR). All constructs were verified by sequencing.
Cell culture and transfection
HeLa cells were cultured in Dulbecco's modified Eagle's medium (DMEM); high glucose supplemented with 10% fetal bovine serum and 5% penicillin (100 U/ml), streptomycin (100 mg/ml) and glutamate (100 mg/ml). The cultures were maintained at 37°C in an atmosphere of 10% CO 2 . The cells were dissociated using trypsinization and plated (0.3ϫ10 -6 cells) onto glass coverslips (24 mm; Fisher Scientific, Braunsweg, Germany) in a six-well plate and transfected after 1 day. Each well of cells was treated with a mixture of 1 μg DNA and 2 μl Fugene 6.0 transfection reagent in serum-free medium (100 μl transfection per well; Roche Diagnostics, Indianapolis, IN). After transfection, the cells were cultured at 37°C for at least 24 hours. HEK 293T cells were cultured in Iscove's modified Dulbecco's medium (IMDM); high glucose supplemented with 10% fetal bovine serum and 5% penicillin (100 U/ml), streptomycin (100 mg/ml) and glutamate (100 mg/ml) in an atmosphere of 5% CO 2 . One day before transfection, 0.1ϫ10 -6 cells were seeded into 12-well plates and transiently transfected with 0.5 μg DNA using Fugene reagent. After transfection, the cells were cultured at 37°C for 48 hours.
Live cell microscopy
Before imaging, the culture medium was replaced by Hank's balanced salt solution containing CaCl 2 supplemented with 5 mM HEPES. Translocation analysis was performed by confocal microscopy (Leica Sp2) using a 63ϫ objective at room temperature (21-25°C). Fluorescent images of GFP and RFP constructs were obtained in sequential mode. The time-lapse experiments were controlled by the manufacturer's acquisition software and the images were acquired every 12 seconds. To measure kinase activity in single living cells, the FRET reporter MyrPalm-CKAR was imaged on a Zeiss 200M inverted fluorescence microscope equipped with a 40ϫ Plan-Neofluar (1.3 NA) oil-immersion lens (Zeiss, Oberkochen, Germany). The set-up was controlled by MetaMorph software. Excitation light from a Cairn Xenon Arc lamp was selected by a monochromator (Cairn Research, Kent, UK) (420 nm, bandwidth 30 nm) and reflected by a 455DCLP dichroic mirror. Emission was passed through 470/30 nm (CFP) and 535/30 nm (YFP) band-pass filters. Images were acquired with a Photometrics CoolSnap HQ CCD camera with 4ϫ4 binning and an exposure time of 200 ms per image. The time interval was 4 seconds and 121 images were acquired. The average fluorescence intensity of individual cells was measured using ImageJ (http://rsb.info.nih.gov/ij/), background subtracted and normalized to the initial fluorescence. Subsequently the YFP/CFP ratio was calculated as a measure of kinase activity. FLIM experiments and subsequent image analysis were performed as described (Goedhart et al., 2007) . A 442 nm helium-cadmium laser (125 mW, MellesGriot, Carlsbad, CA) was intensity modulated at a frequency of 75.1 MHz. The light was reflected by a 455DCLP dichroic mirror and the CFP emission was passed through a D480/40 band-pass emission filter (Chroma Technology). A 63ϫ objective (Plan Apochromat NA 1.4 oil) was used for all measurements. The FRET efficiency E was calculated according to: E=(1-(τ DA /τ D ))ϫ100% in which τ DA is the fluorescence lifetime of the donor in presence of the acceptor (i.e. the PKC FRET constructs) and τ D is the fluorescence lifetime of the donor (i.e. unfused SCFP3A) in absence of the acceptor. Since frequency domain FLIM yields a phase lifetime and a modulation lifetime, the FRET efficiency can be calculated based on τ π and τ M .
Immunoblotting
The cells were harvested 48 hours after transfection and lysed with ice-cold 2ϫ Tris buffer (100 mM Tris-HCl pH 7.5, 300 mM NaCl, 10 mM EDTA pH 8.0, 1% Triton-X100) supplemented with complete mini protease inhibitor cocktail (Roche, Palo Alto, CA) and phosphatase inhibitor cocktail (Sigma). Cell lysates were incubated for 30 minutes on ice and centrifuged at 14,000 r.p.m. for 20 minutes at 4°C. Protein concentrations in the lysates were determined with the Bradford protein assay and equal protein levels were loaded on 10% SDS-PAGE gels. After electrophoresis, the proteins were transferred onto a nitrocellulose membrane filter (Schleicher & Schuell, Dassel, Germany) and blocked in 5% milk to prepare for western blotting. The western blots were analyzed with anti-PKC (α,β and γ; Upstate), anti-GFP (Santa Cruz), antiphospho-(Ser)-PKC-substrate (Cell Signaling), anti-phosho-p44/42-MAP kinase (Thr202/Tyr204) (Cell Signaling), anti-p44/42 MAP kinase (Cell Signaling), anti-MARCKS phosphoSer152/156 (Chemicon), and anti-MARKCS (Chemicon) antibodies.
